Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancerF Mosele, B Stefanovska, A Lusque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumorsS J Isakoff, J Tabernero, L R Molife, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerA J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Neuro-Chirurgie|May 27, 2014
[Chordoma]B George, D Bresson, S Bouazza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 31, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperS Champiat, O Lambotte, E Barreau, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewJ M Michot, C Bigenwald, S Champiat, et al.
Pageof 26